omeprazole has been researched along with Hyperplasia in 55 studies
Omeprazole: A 4-methoxy-3,5-dimethylpyridyl, 5-methoxybenzimidazole derivative of timoprazole that is used in the therapy of STOMACH ULCERS and ZOLLINGER-ELLISON SYNDROME. The drug inhibits an H(+)-K(+)-EXCHANGING ATPASE which is found in GASTRIC PARIETAL CELLS.
omeprazole : A racemate comprising equimolar amounts of (R)- and (S)-omeprazole.
5-methoxy-2-{[(4-methoxy-3,5-dimethylpyridin-2-yl)methyl]sulfinyl}-1H-benzimidazole : A member of the class of benzimidazoles that is 1H-benzimidazole which is substituted by a [4-methoxy-3,5-dimethylpyridin-2-yl)methyl]sulfinyl group at position 2 and a methoxy group at position 5.
Hyperplasia: An increase in the number of cells in a tissue or organ without tumor formation. It differs from HYPERTROPHY, which is an increase in bulk without an increase in the number of cells.
| Excerpt | Relevance | Reference |
|---|---|---|
| " pylori infection on gastritis, enterochromaffin-like cell density and hyperplasia, mucosal atrophy and serum gastrin in patients with gastric hypersecretion (basal acid output gt; 15 mmol/h) with either hypergastrinemia (Zollinger-Ellison syndrome) or normal gastrin (non-Zollinger-Ellison syndrome) before and during long-term treatment with lansoprazole." | 7.71 | Helicobacter pylori effects on gastritis, gastrin and enterochromaffin-like cells in Zollinger-Ellison syndrome and non-Zollinger-Ellison syndrome acid hypersecretors treated long-term with lansoprazole. ( Haber, MM; Hirschowitz, BI, 2001) |
| " We report data from patients with refractory reflux esophagitis who were undergoing maintenance therapy with >/=20 mg omeprazole daily for a mean period of 6." | 7.70 | Long-term omeprazole treatment in resistant gastroesophageal reflux disease: efficacy, safety, and influence on gastric mucosa. ( Dent, J; Frame, MH; Havu, N; Klinkenberg-Knol, EC; Lloyd, D; Mitchell, B; Nelis, F; Prichard, P; Romàn, J; Snel, P; Walan, A, 2000) |
| " pylori represents an important factor for the progression of fundic gastritis and the development of argyrophil cell hyperplasia during long-term treatment with lansoprazole." | 7.69 | Gastric mucosa during treatment with lansoprazole: Helicobacter pylori is a risk factor for argyrophil cell hyperplasia. ( Arnold, R; Brunner, G; Eissele, R; Simon, B; Solcia, E, 1997) |
| "Long-term treatment with omeprazole induces hyperplasia of enterochromaffin-like cells, closely related to hypergastrinemia." | 7.68 | Effects of proglumide and enprostil on omeprazole-induced fundic endocrine cell hyperplasia in rats. ( Belaïche, J; Delwaide, J; Gast, P; Latour, P; Louis, E, 1993) |
| "In the present study, gastric pH was lowered by hydrochloric acid to investigate whether the cause of enterochromaffin-like (ECL) cell hyperplasia was due to the inhibition of acid secretion by omeprazole or due to the direct action of the drug." | 7.68 | Effects of hydrochloric acid on the development of enterochromaffin-like (ECL) cell hyperplasia in the rat stomach induced by omeprazole. ( Fujihira, S; Fujii, T; Matsuo, M; Oishi, Y; Tomoi, M, 1993) |
| " The present study shows that the combination of portacaval shunting and omeprazole-evoked, long-lasting hypergastrinemia results in enhanced enterochromaffinlike cell hyperplasia despite the fact that the hypergastrinemia was not significantly greater than in intact omeprazole-treated rats." | 7.68 | Enhanced hyperplasia of gastric enterochromaffinlike cells in response to omeprazole-evoked hypergastrinemia in rats with portacaval shunts. An immunocytochemical and chemical study. ( Axelson, J; Ekelund, M; Håkanson, R; Sundler, F, 1990) |
| "Development of focal gland atrophy of the oxyntic mucosa was found in two patients with the Zollinger-Ellison syndrome undergoing long-term treatment with omeprazole." | 7.68 | Focal oxyntic gland atrophy with endocrine cell hyperplasia in Zollinger-Ellison syndrome during omeprazole treatment. ( Annibale, B; Azzoni, C; Bertelé, A; Bordi, C; Caruana, P; Delle Fave, G; Franzé, A, 1992) |
| "Treatment with omeprazole also raised stomach weight and antral gastrin and gastrin cell density, reduced antral somatostatin cell density, but did not affect enterochromaffin cell density." | 5.27 | Time-course of development and reversal of gastric endocrine cell hyperplasia after inhibition of acid secretion. Studies with omeprazole and ranitidine in intact and antrectomized rats. ( Carlsson, E; Håkanson, R; Larsson, H; Mattsson, H; Nilsson, G; Seensalu, R; Sundler, F; Wallmark, B, 1988) |
| " Investigative studies showed evidence for marked and sustained hypergastrinemia increasing on chronic dosing which was capable of restoring gastric acid secretion and pH to near control values." | 5.27 | Gastric ECL-cell hyperplasia and carcinoids in rodents following chronic administration of H2-antagonists SK&F 93479 and oxmetidine and omeprazole. ( Betton, GR; Buckley, P; Dormer, CS; Pert, P; Price, CA; Wells, T, 1988) |
| "Two hundred and forty-three patients received rabeprazole (20 mg or 10 mg) or omeprazole (20 mg) once daily for up to 5 years, for gastro-oesophageal reflux disease and 51% completed the whole 5 year period." | 5.11 | Effects of 5 years of treatment with rabeprazole or omeprazole on the gastric mucosa. ( Fiocca, R; Jacobs, A; Miller, N; Morocutti, A; Rindi, G; Thjodleifsson, B, 2005) |
| "Gastric ECL-cell hyperplasia and carcinoids (ECLoma) develop after 1 year in rats treated with omeprazole or 2 months in Mastomys treated with loxtidine." | 3.78 | Ultrastructure of ECL cells in Mastomys after long-term treatment with H2 receptor antagonist loxtidine. ( Chen, D; Kidd, M; Modlin, IM; Vigen, RA; Zhao, CM, 2012) |
| " We administered high-dose omeprazole to patients with Barrett's esophagus for 2 years, and investigated changes in gastric ECL (Enterochromaffin-like) cells using endoscopic biopsy specimens to clarify the etiology of hyperplasia of the parietal cells." | 3.73 | Changes in gastric ECL cells and parietal cells after long-term administration of high-dose omeprazole to patients with Barrett's esophagus. ( Makuuchi, H; Nishi, T; Weinstein, WM, 2005) |
| " pylori infection on gastritis, enterochromaffin-like cell density and hyperplasia, mucosal atrophy and serum gastrin in patients with gastric hypersecretion (basal acid output gt; 15 mmol/h) with either hypergastrinemia (Zollinger-Ellison syndrome) or normal gastrin (non-Zollinger-Ellison syndrome) before and during long-term treatment with lansoprazole." | 3.71 | Helicobacter pylori effects on gastritis, gastrin and enterochromaffin-like cells in Zollinger-Ellison syndrome and non-Zollinger-Ellison syndrome acid hypersecretors treated long-term with lansoprazole. ( Haber, MM; Hirschowitz, BI, 2001) |
| " We report data from patients with refractory reflux esophagitis who were undergoing maintenance therapy with >/=20 mg omeprazole daily for a mean period of 6." | 3.70 | Long-term omeprazole treatment in resistant gastroesophageal reflux disease: efficacy, safety, and influence on gastric mucosa. ( Dent, J; Frame, MH; Havu, N; Klinkenberg-Knol, EC; Lloyd, D; Mitchell, B; Nelis, F; Prichard, P; Romàn, J; Snel, P; Walan, A, 2000) |
| "Omeprazole reduced the body weight gain while greatly increasing the weight of the proventriculus and the parathyroid glands." | 3.69 | Growth of the parathyroid glands in omeprazole-treated chickens. ( Gagnemo-Persson, R; Håkanson, R; Persson, P; Sundler, F, 1994) |
| " pylori represents an important factor for the progression of fundic gastritis and the development of argyrophil cell hyperplasia during long-term treatment with lansoprazole." | 3.69 | Gastric mucosa during treatment with lansoprazole: Helicobacter pylori is a risk factor for argyrophil cell hyperplasia. ( Arnold, R; Brunner, G; Eissele, R; Simon, B; Solcia, E, 1997) |
| "Long-term treatment with omeprazole induces hyperplasia of enterochromaffin-like cells, closely related to hypergastrinemia." | 3.68 | Effects of proglumide and enprostil on omeprazole-induced fundic endocrine cell hyperplasia in rats. ( Belaïche, J; Delwaide, J; Gast, P; Latour, P; Louis, E, 1993) |
| " Serum gastrin levels, non-antral gastric endocrine (argyrophil) cell growth, and the severity and type of concomitant gastritis were monitored in 66 unoperated and 8 antrectomized patients with poorly responsive peptic ulcer or reflux oesophagitis during up to 5 years' treatment with high-dose omeprazole, 40 mg daily." | 3.68 | Inter-relationship between serum gastrin levels, gastric mucosal histology and gastric endocrine cell growth. ( Creutzfeldt, W; Lamberts, R, 1992) |
| "Biopsy specimens from the oxyntic mucosa were obtained on 210 occasions from 76 patients with the Zollinger-Ellison syndrome (ZES) before and during omeprazole treatment." | 3.68 | Stereologic investigations of human gastric mucosa. II. Oxyntic mucosa from patients with Zollinger-Ellison syndrome. ( Gardner, JD; Helander, HF; Helander, KG; Jensen, RT; Maton, PN; Pisegna, JP; Rutgersson, K, 1992) |
| " The present study shows that the combination of portacaval shunting and omeprazole-evoked, long-lasting hypergastrinemia results in enhanced enterochromaffinlike cell hyperplasia despite the fact that the hypergastrinemia was not significantly greater than in intact omeprazole-treated rats." | 3.68 | Enhanced hyperplasia of gastric enterochromaffinlike cells in response to omeprazole-evoked hypergastrinemia in rats with portacaval shunts. An immunocytochemical and chemical study. ( Axelson, J; Ekelund, M; Håkanson, R; Sundler, F, 1990) |
| "The histamine-producing enterochromaffin-like (ECL) cells in the acid-producing portion of the rat stomach responded to long-standing hypergastrinemia (omeprazole treatment daily for 8-10 weeks) with hypertrophy (and hyperplasia) and with a reduced number of granules and vesicles per unit cytoplasm." | 3.68 | Effect of omeprazole-evoked hypergastrinemia on ultrastructure of enterochromaffin-like cells in the stomach of portacaval-shunted rats. ( Chen, D; Håkanson, R; Sundler, F, 1993) |
| "Relapses were re-treated with omeprazole 40 mg; upon rehealing, patients were put on maintenance omeprazole 20 mg daily for up to 4." | 2.68 | Histamine H2 receptor antagonist-refractory oesophagitis: the efficacy of long-term omeprazole maintenance treatment. ( Bardhan, KD; Bishop, A; Brooks, A; Cherian, P; D'Silva, J; Gillon, KR; Jones, RB; Manek, S; Morris, P; Parkin, S; Patterson, J; Polak, J; Thompson, M; Vaishnavi, A, 1997) |
| " No significant pathological findings were noted, and no adverse events were attributable to the study treatments." | 2.67 | Omeprazole v ranitidine for prevention of relapse in reflux oesophagitis. A controlled double blind trial of their efficacy and safety. ( Dent, J; Hetzel, DJ; Mackinnon, M; Narielvala, FM; Reed, W; Shearman, DJ; Solcia, E; Yeomans, ND, 1994) |
| "Although basal cell hyperplasia is a histologic hallmark of eosinophilic esophagitis (EoE), little is known about the capabilities of epithelial renewal and differentiation in the EoE inflammatory milieu." | 1.72 | CD73 ( Aaron, B; Dolinsky, L; Hamilton, KE; Hara, T; Karakasheva, TA; Karami, A; Kasagi, Y; Klein, J; Lynch, K; Maekawa, H; Muir, AB; Nakagawa, H; Nunes, K; Ruffner, MA; Sasaki, M; Shimonosono, M; Shimonosono, R; Spergel, JM; Wang, J; Wei, J; Whelan, KA; Wilkins, B, 2022) |
| "Omeprazole treatment for 4 weeks increased the oxyntic mucosal weight and thickness by 15-20%." | 1.31 | Effects of CCK2 receptor blockade on growth parameters in gastrointestinal tract and pancreas in rats. ( Björkqvist, M; Chen, D; de la Cour, CD; Gagnemo-Persson, C; Håkanson, R; Kitano, M; Norlén, P; Zhao, CM, 2001) |
| "Twenty-one families with MEN 2 (16 families with MEN 2A and 5 families with MEN 2B) were studied." | 1.31 | Very early detection of RET proto-oncogene mutation is crucial for preventive thyroidectomy in multiple endocrine neoplasia type 2 children: presence of C-cell malignant disease in asymptomatic carriers. ( Barontini, M; de, M; Domene, HM; Elsner, B; Garcia, R; Iorcansky, S; Perinetti, H; Pusiol, E; Ring, A; Roque, M; Sanso, GE, 2002) |
| "None of the rats developed esophageal cancer, but esophageal mucosal hyperplasia was more pronounced in rats receiving omeprazole." | 1.30 | Gastric acid blockade with omeprazole promotes gastric carcinogenesis induced by duodenogastric reflux. ( Adrian, TE; Hinder, RA; Perdikis, G; Profanter, C; Smyrk, T; Wetscher, GJ, 1999) |
| "Omeprazole is a proton pump inhibitor of increasingly wide use in the treatment of peptic ulcers." | 1.29 | Lack of evidence of omeprazole genotoxicity in Sprague-Dawley rats. ( Brambilla, G; Ghia, M; Martelli, A; Mereto, E, 1993) |
| "We investigated whether duodenogastric reflux (DGR) together with gastroesophageal reflux causes growth stimulation of the foregut mucosa and if additional gastric acid suppression enhances the effect of DGR." | 1.29 | Duodenogastric reflux causes growth stimulation of foregut mucosa potentiated by gastric acid blockade. ( Adrian, TE; Hinder, RA; Klingler, PJ; Kretchmar, D; Perdikis, G; Smyrk, T; Stinson, R; Wetscher, GJ, 1996) |
| "Chronic atrophic gastritis was found in 45 (10." | 1.28 | Gastric endocrine cells and gastritis in patients receiving long-term omeprazole treatment. ( Carlsson, R; Dalväg, A; Fiocca, R; Havu, N; Solcia, E, 1992) |
| "Neuroendocrine cell (carcinoid) tumours have been reported in the acid-secreting part of the stomach of rodents after long-term administration of a range of potent chemically diverse antisecretory agents." | 1.28 | Potential hazards of long-term acid suppression. ( Selway, SA, 1990) |
| " Investigative studies showed evidence for marked and sustained hypergastrinemia increasing on chronic dosing which was capable of restoring gastric acid secretion and pH to near control values." | 1.27 | Gastric ECL-cell hyperplasia and carcinoids in rodents following chronic administration of H2-antagonists SK&F 93479 and oxmetidine and omeprazole. ( Betton, GR; Buckley, P; Dormer, CS; Pert, P; Price, CA; Wells, T, 1988) |
| "Treatment with omeprazole also raised stomach weight and antral gastrin and gastrin cell density, reduced antral somatostatin cell density, but did not affect enterochromaffin cell density." | 1.27 | Time-course of development and reversal of gastric endocrine cell hyperplasia after inhibition of acid secretion. Studies with omeprazole and ranitidine in intact and antrectomized rats. ( Carlsson, E; Håkanson, R; Larsson, H; Mattsson, H; Nilsson, G; Seensalu, R; Sundler, F; Wallmark, B, 1988) |
| Timeframe | Studies, this research(%) | All Research% |
|---|---|---|
| pre-1990 | 6 (10.91) | 18.7374 |
| 1990's | 33 (60.00) | 18.2507 |
| 2000's | 13 (23.64) | 29.6817 |
| 2010's | 2 (3.64) | 24.3611 |
| 2020's | 1 (1.82) | 2.80 |
| Authors | Studies |
|---|---|
| Hara, T | 1 |
| Kasagi, Y | 1 |
| Wang, J | 1 |
| Sasaki, M | 1 |
| Aaron, B | 1 |
| Karami, A | 1 |
| Shimonosono, M | 1 |
| Shimonosono, R | 1 |
| Maekawa, H | 1 |
| Dolinsky, L | 1 |
| Wilkins, B | 1 |
| Klein, J | 1 |
| Wei, J | 1 |
| Nunes, K | 1 |
| Lynch, K | 1 |
| Spergel, JM | 1 |
| Hamilton, KE | 1 |
| Ruffner, MA | 1 |
| Karakasheva, TA | 1 |
| Whelan, KA | 1 |
| Nakagawa, H | 1 |
| Muir, AB | 1 |
| Tsyriuk, OI | 1 |
| Vigen, RA | 1 |
| Kidd, M | 1 |
| Modlin, IM | 1 |
| Chen, D | 4 |
| Zhao, CM | 3 |
| Brzozowski, T | 1 |
| Konturek, PC | 1 |
| Kwiecien, S | 1 |
| Konturek, SJ | 1 |
| Pajdo, R | 1 |
| Drozdowicz, D | 1 |
| Ptak, A | 1 |
| Pawlik, M | 1 |
| Stachura, J | 1 |
| Pawlik, WW | 1 |
| Hahn, EG | 1 |
| Fukushima, Y | 1 |
| Shindo, T | 1 |
| Anai, M | 1 |
| Saitoh, T | 1 |
| Wang, Y | 1 |
| Fujishiro, M | 1 |
| Ohashi, Y | 1 |
| Ogihara, T | 1 |
| Inukai, K | 1 |
| Ono, H | 1 |
| Sakoda, H | 1 |
| Kurihara, Y | 1 |
| Honda, M | 1 |
| Shojima, N | 1 |
| Fukushima, H | 1 |
| Haraikawa-Onishi, Y | 1 |
| Katagiri, H | 1 |
| Shimizu, Y | 1 |
| Ichinose, M | 1 |
| Ishikawa, T | 1 |
| Omata, M | 1 |
| Nagai, R | 1 |
| Kurihara, H | 1 |
| Asano, T | 1 |
| Rindi, G | 2 |
| Fiocca, R | 2 |
| Morocutti, A | 1 |
| Jacobs, A | 1 |
| Miller, N | 1 |
| Thjodleifsson, B | 1 |
| Nishi, T | 1 |
| Makuuchi, H | 1 |
| Weinstein, WM | 1 |
| Declich, P | 3 |
| Omazzi, B | 1 |
| Tavani, E | 3 |
| Bellone, S | 3 |
| Gozzini, C | 2 |
| Bortoli, A | 2 |
| Prada, A | 2 |
| Handa, Y | 1 |
| Ietomi, K | 1 |
| Sakimura, K | 1 |
| Miyoshi, K | 1 |
| Mereto, E | 1 |
| Ghia, M | 1 |
| Martelli, A | 1 |
| Brambilla, G | 1 |
| Tanaka, J | 1 |
| Fujimoto, K | 1 |
| Iwakiri, R | 1 |
| Koyama, T | 1 |
| Sakata, H | 1 |
| Ohyama, T | 1 |
| Mizuguchi, M | 1 |
| Tokunaga, O | 1 |
| Gagnemo-Persson, R | 1 |
| Håkanson, R | 11 |
| Sundler, F | 9 |
| Persson, P | 1 |
| Delwaide, J | 1 |
| Latour, P | 1 |
| Gast, P | 1 |
| Louis, E | 1 |
| Belaïche, J | 1 |
| Dent, J | 2 |
| Yeomans, ND | 1 |
| Mackinnon, M | 1 |
| Reed, W | 1 |
| Narielvala, FM | 1 |
| Hetzel, DJ | 1 |
| Solcia, E | 4 |
| Shearman, DJ | 1 |
| Fujii, T | 1 |
| Oishi, Y | 1 |
| Fujihira, S | 1 |
| Matsuo, M | 1 |
| Tomoi, M | 1 |
| Driman, DK | 1 |
| Wright, C | 1 |
| Tougas, G | 1 |
| Riddell, RH | 1 |
| Wetscher, GJ | 2 |
| Hinder, RA | 2 |
| Kretchmar, D | 1 |
| Stinson, R | 1 |
| Perdikis, G | 2 |
| Smyrk, T | 2 |
| Klingler, PJ | 1 |
| Adrian, TE | 2 |
| Waldum, HL | 2 |
| Arnestad, JS | 1 |
| Brenna, E | 2 |
| Eide, I | 1 |
| Syversen, U | 1 |
| Sandvik, AK | 2 |
| Eissele, R | 2 |
| Brunner, G | 1 |
| Simon, B | 1 |
| Arnold, R | 2 |
| Suzuki, S | 2 |
| Ohkusa, T | 2 |
| Shimoi, K | 2 |
| Horiuchi, T | 2 |
| Fujiki, K | 2 |
| Takashimizu, I | 2 |
| Bardhan, KD | 1 |
| Cherian, P | 1 |
| Jones, RB | 1 |
| Vaishnavi, A | 1 |
| Manek, S | 1 |
| Bishop, A | 1 |
| Polak, J | 1 |
| Brooks, A | 1 |
| Morris, P | 1 |
| Thompson, M | 1 |
| D'Silva, J | 1 |
| Parkin, S | 1 |
| Patterson, J | 1 |
| Gillon, KR | 1 |
| Kimura, K | 1 |
| Lindström, E | 1 |
| Yamada, H | 1 |
| Diebold, MD | 1 |
| Richardson, S | 1 |
| Duchateau, A | 1 |
| Bigard, MA | 1 |
| Colin, R | 1 |
| Cortot, A | 1 |
| Fauchère, JL | 1 |
| Zeitoun, P | 1 |
| Sakurazawa, T | 1 |
| Ariake, K | 1 |
| Ishii, K | 1 |
| Kumagai, J | 1 |
| Tanizawa, T | 1 |
| Profanter, C | 1 |
| Ambrosiani, L | 2 |
| Robinson, M | 1 |
| Klinkenberg-Knol, EC | 1 |
| Nelis, F | 1 |
| Snel, P | 1 |
| Mitchell, B | 1 |
| Prichard, P | 1 |
| Lloyd, D | 1 |
| Havu, N | 4 |
| Frame, MH | 1 |
| Romàn, J | 1 |
| Walan, A | 1 |
| Bakke, I | 1 |
| Qvigstad, G | 1 |
| Nakajima, A | 1 |
| Matsuhashi, N | 1 |
| Yazaki, Y | 1 |
| Oka, T | 1 |
| Sugano, K | 1 |
| Hirschowitz, BI | 1 |
| Haber, MM | 1 |
| Stolte, M | 1 |
| Vieth, M | 1 |
| Schmitz, JM | 1 |
| Alexandridis, T | 1 |
| Seifert, E | 1 |
| Kume, K | 1 |
| Hirakoba, M | 1 |
| Murata, I | 1 |
| Yoshikawa, I | 1 |
| Otsuki, M | 1 |
| Björkqvist, M | 1 |
| Norlén, P | 1 |
| Kitano, M | 1 |
| de la Cour, CD | 1 |
| Gagnemo-Persson, C | 1 |
| Sanso, GE | 1 |
| Domene, HM | 1 |
| Garcia, R | 1 |
| Pusiol, E | 1 |
| de, M | 1 |
| Roque, M | 1 |
| Ring, A | 1 |
| Perinetti, H | 1 |
| Elsner, B | 1 |
| Iorcansky, S | 1 |
| Barontini, M | 1 |
| Dalväg, A | 1 |
| Carlsson, R | 1 |
| Creutzfeldt, W | 1 |
| Lamberts, R | 1 |
| Caruana, P | 1 |
| Azzoni, C | 1 |
| Bertelé, A | 1 |
| Annibale, B | 1 |
| Franzé, A | 1 |
| Delle Fave, G | 1 |
| Bordi, C | 1 |
| Helander, HF | 1 |
| Rutgersson, K | 1 |
| Helander, KG | 1 |
| Pisegna, JP | 1 |
| Gardner, JD | 1 |
| Jensen, RT | 1 |
| Maton, PN | 1 |
| Andersson, K | 1 |
| Mattsson, H | 5 |
| Ryberg, B | 3 |
| Axelson, J | 3 |
| Tielemans, Y | 1 |
| Johansson, AG | 1 |
| Willems, G | 1 |
| Tielemans, YK | 1 |
| Willems, GE | 1 |
| Selway, SA | 1 |
| Rosskopf, B | 1 |
| Koop, H | 1 |
| Adler, G | 1 |
| Carlsson, E | 4 |
| Ekman, L | 1 |
| Ekelund, M | 1 |
| Elm, G | 1 |
| Bishop, AE | 1 |
| Bloom, SR | 1 |
| Larsson, H | 3 |
| Polak, JM | 1 |
| Betton, GR | 1 |
| Dormer, CS | 1 |
| Wells, T | 1 |
| Pert, P | 1 |
| Price, CA | 1 |
| Buckley, P | 1 |
| Nilsson, G | 1 |
| Seensalu, R | 1 |
| Wallmark, B | 1 |
| Bardram, L | 1 |
| Thomsen, P | 1 |
| Stadil, F | 1 |
| Trial | Phase | Enrollment | Study Type | Start Date | Status | ||
|---|---|---|---|---|---|---|---|
| Study of the Effect of PROGRESSive Withdrawal Esomeprazole of on Acid-related Symptoms, PROGRESS Study A Randomized, Placebo-controlled, Double Blinded Study[NCT02476097] | Phase 4 | 58 participants (Anticipated) | Interventional | 2015-06-30 | Active, not recruiting | ||
| Proton Pump Inhibitors in the Prevention of Iron Reaccumulation in Patient With Hereditary Hemochromatosis[NCT01524757] | 48 participants (Anticipated) | Interventional | 2012-03-31 | Not yet recruiting | |||
| [information is prepared from clinicaltrials.gov, extracted Sep-2024] | |||||||
3 reviews available for omeprazole and Hyperplasia
| Article | Year |
|---|---|
Review article: current perspectives on hypergastrinaemia and enterochromaffin-like-cell hyperplasia.
Topics: 2-Pyridinylmethylsulfinylbenzimidazoles; Animals; Anti-Ulcer Agents; Benzimidazoles; Enterochromaffi | 1999 |
[Effect of endogenous and exogenous gastrin on enterochromaffin-like cell proliferation].
Topics: Animals; Enterochromaffin Cells; Gastric Mucosa; Gastrins; Hyperplasia; Mice; Omeprazole; Rats; Stom | 1991 |
Gastrin and gastric enterochromaffin-like cell carcinoids in the rat.
Topics: Animals; Enterochromaffin Cells; Gastric Mucosa; Gastrins; Hyperplasia; Omeprazole; Ranitidine; Rats | 1990 |
8 trials available for omeprazole and Hyperplasia
| Article | Year |
|---|---|
Effects of 5 years of treatment with rabeprazole or omeprazole on the gastric mucosa.
Topics: 2-Pyridinylmethylsulfinylbenzimidazoles; Adult; Aged; Anti-Ulcer Agents; Benzimidazoles; Biopsy; Dis | 2005 |
Omeprazole v ranitidine for prevention of relapse in reflux oesophagitis. A controlled double blind trial of their efficacy and safety.
Topics: Adolescent; Adult; Aged; Aged, 80 and over; Double-Blind Method; Esophagitis, Peptic; Esophagoscopy; | 1994 |
Marked increase in gastric acid secretory capacity after omeprazole treatment.
Topics: Adult; Aged; Anti-Ulcer Agents; Chromogranin A; Chromogranins; Enterochromaffin Cells; Esophagitis, | 1996 |
Histamine H2 receptor antagonist-refractory oesophagitis: the efficacy of long-term omeprazole maintenance treatment.
Topics: Adult; Aged; Biopsy; Cimetidine; Drug Administration Schedule; Drug Resistance; Enzyme Inhibitors; E | 1997 |
Factors influencing corpus argyrophil cell density and hyperplasia in reflux esophagitis patients treated with antisecretory drugs and controls.
Topics: Adult; Aged; Aged, 80 and over; Anti-Ulcer Agents; Cell Count; Cross-Sectional Studies; Enterochroma | 1998 |
Disappearance of hyperplastic polyps in the stomach after eradication of Helicobacter pylori. A randomized, clinical trial.
Topics: 2-Pyridinylmethylsulfinylbenzimidazoles; Abietanes; Adult; Aged; Amoxicillin; Anti-Bacterial Agents; | 1998 |
Effects of long-term treatment with proton pump inhibitors in gastro-oesophageal reflux disease on the histological findings in the lower oesophagus.
Topics: 2-Pyridinylmethylsulfinylbenzimidazoles; Anti-Ulcer Agents; Barrett Esophagus; Double-Blind Method; | 2000 |
Qualitative studies of gastric endocrine cells in patients treated long-term with omeprazole.
Topics: Biopsy; Carcinoid Tumor; Cell Division; Cell Transformation, Neoplastic; Enterochromaffin Cells; Eso | 1989 |
44 other studies available for omeprazole and Hyperplasia
| Article | Year |
|---|---|
CD73
Topics: 5'-Nucleotidase; Animals; Cytokines; Eosinophilic Esophagitis; Homeostasis; Humans; Hyperplasia; Int | 2022 |
[Correction of negative influence of long-term hypergastrinemia on gastric acid secretion].
Topics: Animals; Anti-Ulcer Agents; Drug Therapy, Combination; Gastric Acid; Gastric Mucosa; Gastrins; Hyper | 2011 |
Ultrastructure of ECL cells in Mastomys after long-term treatment with H2 receptor antagonist loxtidine.
Topics: Animals; Anti-Ulcer Agents; Autophagy; Carcinoid Tumor; Enterochromaffin-like Cells; Female; Histami | 2012 |
Triple eradication therapy counteracts functional impairment associated with Helicobacter pylori infection in Mongolian gerbils.
Topics: Amoxicillin; Animals; Anti-Ulcer Agents; Colony Count, Microbial; Drug Therapy, Combination; Gastric | 2003 |
Structural and functional characterization of gastric mucosa and central nervous system in histamine H2 receptor-null mice.
Topics: 2-Pyridinylmethylsulfinylbenzimidazoles; Animals; Blotting, Northern; Electroshock; Gastric Acid; Ga | 2003 |
Changes in gastric ECL cells and parietal cells after long-term administration of high-dose omeprazole to patients with Barrett's esophagus.
Topics: Anti-Ulcer Agents; Barrett Esophagus; Cell Count; Dose-Response Relationship, Drug; Enterochromaffin | 2005 |
Fundic gland polyps and PPI: the Mozart effect of gastrointestinal pathology?
Topics: Enzyme Inhibitors; Gastric Fundus; Helicobacter Infections; Helicobacter pylori; Humans; Hyperplasia | 2006 |
[A case of multiple gastric hyperplastic polyps: onset during omeprazole therapy in scleroderma patient].
Topics: Aged; Esophagitis, Peptic; Female; Humans; Hyperplasia; Omeprazole; Polyps; Scleroderma, Systemic; S | 1994 |
Lack of evidence of omeprazole genotoxicity in Sprague-Dawley rats.
Topics: Animals; Cell Nucleus; Chi-Square Distribution; DNA Damage; Enzyme Induction; Female; gamma-Glutamyl | 1993 |
Hyperplastic polyps following treatment of acute gastric ulcers.
Topics: Esophageal and Gastric Varices; Famotidine; Female; Humans; Hyperplasia; Middle Aged; Omeprazole; Po | 1994 |
Growth of the parathyroid glands in omeprazole-treated chickens.
Topics: Animals; Bone Density; Chickens; DNA; Gastrins; Hyperplasia; Hypertrophy; Omeprazole; Organ Size; Pa | 1994 |
Effects of proglumide and enprostil on omeprazole-induced fundic endocrine cell hyperplasia in rats.
Topics: Animals; Cell Count; Depression, Chemical; Drug Combinations; Enprostil; Enterochromaffin Cells; Fem | 1993 |
Effects of hydrochloric acid on the development of enterochromaffin-like (ECL) cell hyperplasia in the rat stomach induced by omeprazole.
Topics: Animals; Enterochromaffin Cells; Female; Gastric Acid; Gastric Acidity Determination; Hydrochloric A | 1993 |
Effect of omeprazole-evoked hypergastrinemia on ultrastructure of enterochromaffin-like cells in the stomach of portacaval-shunted rats.
Topics: Animals; Enterochromaffin Cells; Gastrins; Hyperplasia; Hypertrophy; Male; Microscopy, Electron; Ome | 1993 |
Omeprazole produces parietal cell hypertrophy and hyperplasia in humans.
Topics: Adolescent; Adult; Aged; Aged, 80 and over; Anti-Ulcer Agents; Cell Count; Cell Size; Humans; Hyperp | 1996 |
Duodenogastric reflux causes growth stimulation of foregut mucosa potentiated by gastric acid blockade.
Topics: Animals; DNA; Duodenogastric Reflux; Esophagus; Gastric Acid; Gastric Acidity Determination; Gastric | 1996 |
Gastric mucosa during treatment with lansoprazole: Helicobacter pylori is a risk factor for argyrophil cell hyperplasia.
Topics: 2-Pyridinylmethylsulfinylbenzimidazoles; Adult; Aged; Female; Gastric Mucosa; Gastrins; Gastritis; H | 1997 |
Disappearance of multiple hyperplastic polyps after the eradication of Helicobacter pylori.
Topics: 2-Pyridinylmethylsulfinylbenzimidazoles; Amoxicillin; Anti-Bacterial Agents; Drug Therapy, Combinati | 1997 |
Functional impairment of the individual rat stomach ECL cell in response to sustained hypergastrinemia.
Topics: Animals; Base Sequence; Cell Size; Chromogranin A; Chromogranins; Enterochromaffin-like Cells; Enzym | 1997 |
Gastric acid blockade with omeprazole promotes gastric carcinogenesis induced by duodenogastric reflux.
Topics: Adenocarcinoma; Animals; Anti-Ulcer Agents; Disease Models, Animal; Duodenogastric Reflux; Esophagea | 1999 |
Fundic metaplasia with parietal cell hyperplasia of the antrum: a lesion possibly associated with long term use of omeprazole.
Topics: Anti-Ulcer Agents; Biopsy; Gastric Fundus; Humans; Hyperplasia; Long-Term Care; Male; Metaplasia; Mi | 1999 |
Corpus-active gastritis with focal atrophy and parietal cell hyperplasia related to long-term use of omeprazole.
Topics: Atrophy; Gastritis; Humans; Hyperplasia; Omeprazole; Parietal Cells, Gastric; Stomach; Time Factors | 1999 |
Long-term omeprazole treatment in resistant gastroesophageal reflux disease: efficacy, safety, and influence on gastric mucosa.
Topics: Adolescent; Adult; Aged; Aged, 80 and over; Anti-Ulcer Agents; Barrett Esophagus; Child; Drug Resist | 2000 |
Gastrin has a specific proliferative effect on the rat enterochromaffin-like cell, but not on the parietal cell: a study by elutriation centrifugation.
Topics: 2-Pyridinylmethylsulfinylbenzimidazoles; Animals; Benzimidazoles; Cell Division; Cell Fractionation; | 2000 |
Details of hyperplastic polyps of the stomach shrinking after anti-Helicobacter pylori therapy.
Topics: Anti-Bacterial Agents; Anti-Ulcer Agents; Biomarkers, Tumor; Cell Division; Cyclooxygenase 2; Drug T | 2000 |
Helicobacter pylori effects on gastritis, gastrin and enterochromaffin-like cells in Zollinger-Ellison syndrome and non-Zollinger-Ellison syndrome acid hypersecretors treated long-term with lansoprazole.
Topics: 2-Pyridinylmethylsulfinylbenzimidazoles; Adult; Enterochromaffin-like Cells; Enzyme Inhibitors; Fema | 2001 |
Disappearance of both MALT lymphoma and hyperplastic polyps in the stomach after eradication of Helicobacter pylori.
Topics: Amoxicillin; Anti-Bacterial Agents; Anti-Ulcer Agents; Clarithromycin; Female; Helicobacter Infectio | 2001 |
Effects of CCK2 receptor blockade on growth parameters in gastrointestinal tract and pancreas in rats.
Topics: Animals; Benzodiazepines; Benzodiazepinones; Digestive System; Drug Interactions; Gastrins; Hormone | 2001 |
Very early detection of RET proto-oncogene mutation is crucial for preventive thyroidectomy in multiple endocrine neoplasia type 2 children: presence of C-cell malignant disease in asymptomatic carriers.
Topics: Adolescent; Adult; Aged; Aged, 80 and over; Calcitonin; Carcinoma, Medullary; Catecholamines; Child; | 2002 |
Gastric endocrine cells and gastritis in patients receiving long-term omeprazole treatment.
Topics: Adult; Biopsy; Esophagitis, Peptic; Gastric Mucosa; Gastritis, Atrophic; Humans; Hyperplasia; Incide | 1992 |
Inter-relationship between serum gastrin levels, gastric mucosal histology and gastric endocrine cell growth.
Topics: Biopsy; Esophagitis, Peptic; Gastric Mucosa; Gastrins; Gastritis, Atrophic; Humans; Hyperplasia; Lon | 1992 |
Focal oxyntic gland atrophy with endocrine cell hyperplasia in Zollinger-Ellison syndrome during omeprazole treatment.
Topics: Adult; Atrophy; Endocrine Glands; Female; Humans; Hyperplasia; Male; Middle Aged; Omeprazole; Pariet | 1992 |
Stereologic investigations of human gastric mucosa. II. Oxyntic mucosa from patients with Zollinger-Ellison syndrome.
Topics: Adolescent; Adult; Age Factors; Aged; Biopsy; Cell Count; Evaluation Studies as Topic; Female; Gastr | 1992 |
Hyperplasia of histamine-depleted enterochromaffinlike cells in rat stomach using omeprazole and alpha-fluoromethylhistidine.
Topics: Animals; Enterochromaffin Cells; Female; Gastric Mucosa; Gastrins; Histamine; Histidine Decarboxylas | 1992 |
Antrectomy does not accelerate reversal of omeprazole-induced trophic effects in the rat stomach.
Topics: Animals; Atrophy; Cell Count; Cell Survival; Gastric Mucosa; Gastrins; Hyperplasia; Male; Omeprazole | 1992 |
Unilateral vagal denervation suppresses omeprazole-induced trophic effects on the denervated side of the rat stomach.
Topics: Animals; Denervation; Enterochromaffin Cells; Gastric Mucosa; Gastrins; Hyperplasia; Male; Omeprazol | 1992 |
Potential hazards of long-term acid suppression.
Topics: Animals; Carcinoid Tumor; Female; Gastric Acid; Gastric Mucosa; Gastrins; Histamine H2 Antagonists; | 1990 |
Proliferation of endocrine cells in the rat stomach caused by drug-induced achlorhydria.
Topics: 2-Pyridinylmethylsulfinylbenzimidazoles; Achlorhydria; Animals; Cell Count; Enterochromaffin Cells; | 1991 |
Enhanced hyperplasia of gastric enterochromaffinlike cells in response to omeprazole-evoked hypergastrinemia in rats with portacaval shunts. An immunocytochemical and chemical study.
Topics: Animals; Chromaffin System; Enterochromaffin Cells; Gastric Mucosa; Gastrins; Histamine; Histidine D | 1990 |
Omeprazole and ranitidine, antisecretagogues with different modes of action, are equally effective in causing hyperplasia of enterochromaffin-like cells in rat stomach.
Topics: Animals; Chromaffin System; Enterochromaffin Cells; Female; Gastric Acid; Gastric Mucosa; Gastrins; | 1989 |
Gastric ECL-cell hyperplasia and carcinoids in rodents following chronic administration of H2-antagonists SK&F 93479 and oxmetidine and omeprazole.
Topics: Animals; Carcinogens; Carcinoid Tumor; Enterochromaffin Cells; Female; Gastric Acid; Gastric Mucosa; | 1988 |
Time-course of development and reversal of gastric endocrine cell hyperplasia after inhibition of acid secretion. Studies with omeprazole and ranitidine in intact and antrectomized rats.
Topics: Animals; Cell Count; Chromaffin System; Enterochromaffin Cells; Female; Gastric Acid; Gastric Mucosa | 1988 |
Omeprazole: its influence on gastric acid secretion, gastrin and ECL cells.
Topics: Animals; Chromaffin System; Dogs; Enterochromaffin Cells; Gastric Acid; Gastric Mucosa; Gastrins; Hy | 1988 |
Gastric endocrine cells in omeprazole-treated and untreated patients with the Zollinger-Ellison syndrome.
Topics: Female; Gastric Mucosa; Gastrins; Humans; Hyperplasia; Male; Omeprazole; Time Factors; Zollinger-Ell | 1986 |